UK Launches AdvanceGxP to Speed Up AI-Powered and Personalised Medicine Manufacturing

UK Launches AdvanceGxP to Speed Up AI-Powered and Personalised Medicine Manufacturing

by Francis Basil
Futuristic pharmaceutical manufacturing facility featuring robotics, artificial intelligence and personalised medicine technology, illustrating the UK's new MHRA AdvanceGxP initiative.

The UK government is backing a new regulatory support initiative designed to help companies develop innovative ways of manufacturing medicines, including personalised treatments produced near hospitals, artificial intelligence-powered production systems and experimental technologies that could eventually enable medicines to be manufactured in space.

The initiative, known as AdvanceGxP, is being developed by the Medicines and Healthcare products Regulatory Agency (MHRA) with funding from the Office for Life Sciences (OLS).

It aims to give pharmaceutical companies, researchers and technology developers access to specialist regulatory advice earlier in the development process, helping them identify potential safety, quality and manufacturing problems before they lead to expensive redesigns or delays.

The announcement was made by Science, Innovation and Investment Minister Chris McDonald MP on 17 November 2026 during the inaugural DIA-MHRA Global Summit in London, held as part of London Life Sciences Week.

The government hopes the programme will strengthen Britain’s position as a centre for pharmaceutical innovation, encourage investment in advanced manufacturing and ultimately help promising treatments reach patients sooner.

However, AdvanceGxP is still being developed and tested. It does not mean that new medicines have already been approved or that patients will immediately gain access to the technologies covered by the initiative.

What is AdvanceGxP and how will it work?

AdvanceGxP is a proposed MHRA support service intended to help organisations understand how existing regulatory and quality requirements apply to new medicine manufacturing technologies.

Pharmaceutical manufacturing is governed by strict standards designed to ensure that medicines are consistently produced, properly controlled and suitable for use by patients.

These standards include Good Practice requirements, which cover different stages of medicine development, production, testing and distribution.

While these rules are well established for conventional pharmaceutical manufacturing, emerging technologies can raise questions about how the requirements should be applied.

For example, a company developing a small, automated manufacturing unit inside a hospital may face different practical challenges from a pharmaceutical manufacturer operating a large centralised factory.

Similarly, a business using artificial intelligence to control parts of its production process may need to demonstrate how the technology is monitored, validated and kept within appropriate quality standards.

AdvanceGxP is intended to help developers address such questions before they become major obstacles.

Rather than waiting until a product or manufacturing system is close to completion, participating organisations would be able to seek specialist guidance earlier, when changes may be easier and less expensive to make.

Personalised medicines could be produced closer to patients

One of the most promising areas highlighted by the MHRA is the development of personalised medicines that can be manufactured at or near hospitals and clinics.

Traditional pharmaceutical manufacturing often involves producing large quantities of standardised medicines at central facilities before distributing them to hospitals, pharmacies and other healthcare providers.

Personalised treatments can require a different approach because they may be designed around an individual patient’s biological characteristics or specific medical needs.

Some advanced therapies, including certain cell-based treatments, involve complex manufacturing processes that may benefit from being located closer to where patients receive care.

Producing treatments near hospitals could potentially reduce some logistical challenges and make certain manufacturing approaches more responsive to individual patient needs.

However, these models also raise important questions about maintaining consistent quality across different locations, monitoring production equipment and ensuring that every treatment meets the necessary standards.

The MHRA believes earlier regulatory engagement could help developers find practical solutions to these challenges.

The aim is not to weaken medicine safety requirements but to help companies understand how they can meet those requirements when using unfamiliar production methods.

How AI, robotics and automation could transform medicine manufacturing

Artificial intelligence, robotics and automation are increasingly being explored as ways to improve the efficiency and consistency of pharmaceutical production.

Automated systems may be able to carry out repetitive manufacturing tasks with greater precision, while advanced monitoring technologies could help identify changes in production conditions.

AI-based systems may also assist with analysing manufacturing data, detecting unusual patterns and supporting decisions about process performance.

These technologies could offer opportunities to reduce waste, improve productivity and make some manufacturing processes more adaptable.

However, they also create regulatory challenges.

For example, manufacturers may need to explain how an AI system makes or supports decisions, how its performance is tested and what safeguards are in place if the technology produces unexpected results.

Robotic manufacturing systems must also be properly maintained, controlled and validated to ensure that the medicines they produce remain consistent and safe.

AdvanceGxP is intended to provide earlier access to MHRA expertise so that developers can address these issues while their technologies are still being designed.

This could help prevent companies from investing heavily in systems that later require substantial changes to meet regulatory expectations.

Could medicines really be manufactured in space?

The MHRA’s announcement also identifies manufacturing in space as an example of the emerging technologies that are changing how scientists think about medicine production.

Research into manufacturing under microgravity conditions has attracted interest because materials and biological processes can behave differently in space compared with conditions on Earth.

Scientists are investigating whether these differences could offer advantages for certain pharmaceutical processes, including aspects of biological research and material formation.

However, space-based medicine manufacturing remains an emerging field, and its commercial and clinical applications are still being explored.

The inclusion of space manufacturing in the MHRA announcement should not be interpreted as confirmation that medicines produced in orbit are about to become routinely available through the NHS.

Instead, it demonstrates the range of technological developments that regulators may need to consider as pharmaceutical manufacturing evolves.

Any medicines produced through new methods would still need to meet the applicable standards for quality, safety and effectiveness before they could be supplied to patients.

MHRA to recruit specialist team with new government funding

Funding from the Office for Life Sciences will allow the MHRA to begin developing AdvanceGxP and recruit a specialist team to support the initiative.

The team will help shape how the service operates and determine how organisations can access regulatory advice.

The development process will also consider which technologies and projects should receive priority and how AdvanceGxP will work alongside existing MHRA support services.

Initial capacity is expected to be limited while the approach is tested.

This means the programme is not yet a fully established service available to every pharmaceutical company or research organisation.

The MHRA intends to use the early development period to assess demand, refine its approach and consider how the service could operate sustainably over the longer term.

If the initial work proves successful, the agency may explore opportunities to expand access in the future.

UK government wants to attract more life sciences investment

The AdvanceGxP initiative forms part of the government’s wider ambition to strengthen the UK’s life sciences industry and encourage companies to develop and manufacture advanced medicines in Britain.

The life sciences sector includes pharmaceutical companies, biotechnology businesses, medical technology developers, research organisations and specialist manufacturers.

These businesses contribute to scientific research, employment, investment and the development of new treatments.

However, competition for international life sciences investment is intense, with countries seeking to attract companies that can create skilled jobs and develop valuable technologies.

The government believes that a regulatory environment capable of responding to innovation could become an important competitive advantage.

Office for Life Sciences Director Kenan Poleo said the UK’s regulatory system could help attract investment by giving companies greater confidence to develop transformative technologies in the country.

The underlying argument is that businesses may be more willing to invest when they can understand regulatory expectations early and reduce uncertainty about whether their manufacturing systems will meet the required standards.

AdvanceGxP is therefore intended to support both patient access to future treatments and the UK’s broader industrial and economic ambitions.

MHRA says early support could reduce delays and encourage innovation

MHRA Chief Executive Lawrence Tallon said the agency wants Britain to be a place where the next generation of innovative medicines can be developed and manufactured.

He explained that providing practical support earlier could help developers resolve problems before they cause delays, increase confidence among investors and make it easier for promising technologies to expand.

The approach reflects a shift towards earlier engagement between regulators and innovators rather than relying solely on regulatory interactions at later stages of development.

For companies working on unfamiliar manufacturing technologies, this could make it easier to identify potential obstacles while there is still time to adjust designs or production processes.

However, earlier advice does not guarantee that a technology will receive regulatory approval.

Developers will still need to demonstrate that their medicines and manufacturing arrangements meet the applicable requirements.

The programme is intended to make the regulatory pathway clearer, not to remove the safeguards that protect patients.

How AdvanceGxP fits into the MHRA Strategy to 2030

The initiative is aligned with the recently launched MHRA Strategy to 2030, which places greater emphasis on early engagement, innovation and collaboration across the health and life sciences sector.

The strategy aims to help the agency respond to scientific and technological developments while maintaining its responsibilities for medicine and medical device regulation.

AdvanceGxP will sit alongside other MHRA initiatives intended to provide more coordinated support to innovators.

The announcement also supports the government’s Life Sciences Sector Plan and wider Industrial Strategy, which identify advanced manufacturing and health innovation as important areas for economic growth.

By helping companies understand regulatory expectations earlier, the MHRA hopes to create conditions in which promising ideas can progress more efficiently from research into manufacturing and, eventually, clinical use.

The effectiveness of the initiative will depend on how it is implemented, the expertise available and whether developers find the support useful in overcoming genuine regulatory challenges.

Announcement made at London Life Sciences Week

AdvanceGxP was announced during the inaugural DIA-MHRA Global Summit, an event jointly hosted by the MHRA and the Drug Information Association.

The summit brought together regulators, pharmaceutical industry representatives, researchers, healthcare professionals and patient advocates to discuss international cooperation and the future of medicine development.

The event formed part of London Life Sciences Week, which showcased the UK’s research, manufacturing and investment capabilities.

Discussions during the week covered areas including women’s health, clinical research, artificial intelligence, advanced therapies, rare diseases and pharmaceutical manufacturing.

The AdvanceGxP announcement reflects the growing recognition that regulators must keep pace with scientific advances if innovative technologies are to move successfully from development into practical healthcare settings.

When will AdvanceGxP become available?

The MHRA has not announced a confirmed date for the full launch of AdvanceGxP.

The funding will initially support recruitment, service design and testing.

During this period, the agency will determine how companies can apply for support, which types of projects will be prioritised and how the new service will connect with existing regulatory programmes.

The initial service is expected to operate with limited capacity, meaning that access may be restricted while the MHRA evaluates its effectiveness.

For patients, this means there is no immediate change to NHS treatment eligibility, prescribing arrangements or access to new medicines as a direct result of the announcement.

The longer-term objective is to help innovative manufacturing technologies overcome avoidable regulatory obstacles so that safe and effective treatments can potentially reach patients more efficiently.

What AdvanceGxP could mean for Nigerians working in UK healthcare and life sciences

For Nigerians living in Britain, the announcement is particularly relevant to professionals already working in healthcare, pharmaceutical research, biotechnology, engineering and digital technology.

The UK’s Nigerian community includes doctors, nurses, pharmacists, laboratory scientists, researchers, engineers and technology specialists whose skills contribute to different parts of the health system.

As medicine manufacturing becomes increasingly automated and data-driven, opportunities may develop for professionals who can combine scientific knowledge with expertise in software, artificial intelligence, robotics, quality assurance and regulatory compliance.

A Nigerian pharmacist or biomedical scientist working in the NHS, for example, may encounter new approaches to producing specialised treatments closer to hospitals. Such developments could eventually change the skills required in certain pharmacy manufacturing units and advanced therapy services.

For Nigerian professionals considering careers beyond frontline clinical practice, the growth of advanced pharmaceutical manufacturing also highlights the importance of fields such as Good Manufacturing Practice, process validation, quality management, regulatory affairs and pharmaceutical data analysis.

However, AdvanceGxP is not itself a recruitment programme, and the announcement does not guarantee new jobs or create a dedicated employment route for overseas professionals.

There is also a potential opportunity for Nigerian-founded technology businesses operating in Britain. Entrepreneurs developing AI systems, laboratory automation, medical manufacturing equipment or pharmaceutical software may find that clearer regulatory guidance helps them understand the standards their products need to meet.

Those opportunities will depend on the eligibility criteria eventually introduced by the MHRA and whether a proposed technology falls within the scope of the service.

For Nigerian patients and families in the UK, the longer-term significance lies in the possibility of more flexible ways to manufacture complex treatments.

Patients living with conditions that require specialised medicines, including some cancers and rare diseases, may eventually benefit if new manufacturing approaches make appropriate treatments easier to produce and deliver.

That potential should not be confused with immediate access. A new regulatory support service does not mean that personalised medicines will suddenly become available at every NHS hospital or that waiting times will automatically fall.

At Chijos News, the significance of AdvanceGxP lies in the connection between Britain’s growing life sciences industry and the Nigerian professionals, entrepreneurs and patients who are part of it. For a Nigerian biomedical scientist seeking to move into pharmaceutical manufacturing, a software engineer building AI tools for healthcare or a family waiting for access to a specialised treatment, the important questions are how these technologies will be regulated, which skills will become valuable and whether innovation will eventually translate into better patient care.

As the MHRA develops the service, the practical developments worth following include its eligibility rules, the technologies selected for early support, the progress of hospital-based medicine manufacturing and whether the programme creates clearer opportunities for smaller innovators alongside established pharmaceutical companies.

For Chijos News readers, those details will matter more than the promise of futuristic technology alone, because the real measure of success will be whether AdvanceGxP helps turn scientific progress into safe, accessible treatments and sustainable opportunities within Britain’s healthcare economy.

You may also like

Leave a Comment

Focus Mode